Alembic Pharmaceuticals Ltd banner

Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 755.95 INR -1.67% Market Closed
Market Cap: ₹148.6B

Alembic Pharmaceuticals Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alembic Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Income from Continuing Operations
₹6.3B
CAGR 3-Years
35%
CAGR 5-Years
-10%
CAGR 10-Years
-1%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
₹55.2B
CAGR 3-Years
15%
CAGR 5-Years
16%
CAGR 10-Years
11%
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
₹45.4B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
₹105.8B
CAGR 3-Years
35%
CAGR 5-Years
41%
CAGR 10-Years
7%
Lupin Ltd
NSE:LUPIN
Income from Continuing Operations
₹46.7B
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
₹22.7B
CAGR 3-Years
40%
CAGR 5-Years
14%
CAGR 10-Years
4%
No Stocks Found

Alembic Pharmaceuticals Ltd
Glance View

Market Cap
148.6B INR
Industry
Pharmaceuticals

Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.

APLLTD Intrinsic Value
861.77 INR
Undervaluation 12%
Intrinsic Value
Price ₹755.95

See Also

What is Alembic Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
6.3B INR

Based on the financial report for Dec 31, 2025, Alembic Pharmaceuticals Ltd's Income from Continuing Operations amounts to 6.3B INR.

What is Alembic Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%

Over the last year, the Income from Continuing Operations growth was 4%. The average annual Income from Continuing Operations growth rates for Alembic Pharmaceuticals Ltd have been 35% over the past three years , -10% over the past five years , and -1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett